Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00351923 |
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
Condition | Intervention | Phase |
---|---|---|
Measles Mumps Rubella Varicella |
Biological: MeMuRu-OKA (study vaccine) |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Open, Multicenter, Randomised, Controlled Phase IIIb Study Evaluating the Immunogenicity and Safety of Subcutaneous Versus Alternative Administration Route of Combined MeMuRu-OKA Vaccine to Healthy Children Aged 11 to 21 Months. |
Ages Eligible for Study: | 11 Months to 22 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Germany, Baden-Wuerttemberg | |
GSK Investigational Site | |
Mannheim, Baden-Wuerttemberg, Germany, 68167 | |
GSK Investigational Site | |
Stuttgart, Baden-Wuerttemberg, Germany, 70469 | |
GSK Investigational Site | |
Tauberbischofsheim, Baden-Wuerttemberg, Germany, 97941 | |
GSK Investigational Site | |
Ettenheim, Baden-Wuerttemberg, Germany, 77955 | |
GSK Investigational Site | |
Bretten, Baden-Wuerttemberg, Germany, 75015 | |
GSK Investigational Site | |
Oberkirch, Baden-Wuerttemberg, Germany, 77704 | |
GSK Investigational Site | |
Kehl, Baden-Wuerttemberg, Germany, 77694 | |
GSK Investigational Site | |
Schwaebisch-Hall, Baden-Wuerttemberg, Germany, 74523 | |
GSK Investigational Site | |
Karlsruhe, Baden-Wuerttemberg, Germany, 76189 | |
GSK Investigational Site | |
Boennigheim, Baden-Wuerttemberg, Germany, 74357 | |
GSK Investigational Site | |
Offenburg, Baden-Wuerttemberg, Germany, 77654 | |
Germany, Hessen | |
GSK Investigational Site | |
Giessen, Hessen, Germany, 35390 | |
GSK Investigational Site | |
Eschwege, Hessen, Germany, 37269 | |
Germany, Rheinland-Pfalz | |
GSK Investigational Site | |
Bad Kreuznach, Rheinland-Pfalz, Germany, 55543 | |
GSK Investigational Site | |
Trier, Rheinland-Pfalz, Germany, 54290 | |
GSK Investigational Site | |
Trier, Rheinland-Pfalz, Germany, 54294 | |
GSK Investigational Site | |
Mainz, Rheinland-Pfalz, Germany, 55131 | |
GSK Investigational Site | |
Worms, Rheinland-Pfalz, Germany, 67547 | |
GSK Investigational Site | |
Mainz, Rheinland-Pfalz, Germany, 55127 | |
GSK Investigational Site | |
Frankenthal, Rheinland-Pfalz, Germany, 67227 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 106670 |
Study First Received: | July 12, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00351923 |
Health Authority: | Germany: Paul-Ehrlich-Institut |
Herpes Zoster Mouth Diseases Paramyxoviridae Infections Measles Chickenpox Healthy Rubella Togaviridae Infections |
Herpesviridae Infections Virus Diseases DNA Virus Infections Chicken pox Stomatognathic Diseases Salivary Gland Diseases Mumps |
Rubivirus Infections Parotid Diseases RNA Virus Infections Morbillivirus Infections |
Rubulavirus Infections Parotitis Mononegavirales Infections |